Liquids rich in noble gas and methods of their preparation and use

Abstract

Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.

1 . A nutraceutical composition for oral delivery, the composition comprising
 a substantially aqueous component comprising a dissolved Xenon gas, a portion of the Xenon gas being encapsulated with a water-soluble polymer,   wherein the water-soluble polymer comprises alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin.   
     
     
         2 - 3 . (canceled) 
     
     
         4 . The composition of  claim 1 , wherein the composition comprises a mixture of two or more Noble gases. 
     
     
         5 . The composition of  claim 1 , wherein the composition comprises an emulsion. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The composition of  claim 1 , wherein the composition comprises about 0.05 to about 2.0 mg/ml of a cyclodextrin molecule. 
     
     
         10 . The composition of  claim 123 , wherein the oil comprises polyunsaturated fatty acids (PUFA). 
     
     
         11 . (canceled) 
     
     
         12 . The composition of  claim 123 , wherein the oil component is saturated with xenon or argon gas. 
     
     
         13 - 17 . (canceled) 
     
     
         18 . The composition of  claim 123 , further defined as an emulsion comprising:
 (a) 15% to 75% by volume oil, said oil being saturated with a Noble gas; and   (b) 25% to 85% by volume aqueous solution.   
     
     
         19 . (canceled) 
     
     
         20 . The composition of  claim 1 , further comprising phospholipid, detergent, or protein components. 
     
     
         21 - 24 . (canceled) 
     
     
         25 . The composition of  claim 123 , further comprising between about 1 and 50 g of xenon per ml of oil. 
     
     
         26 . The composition of  claim 123 , comprising:
 (a) 15% to 75% by volume olive oil, said oil being saturated with xenon or argon gas; (b) 25% to 85% by volume aqueous solution; and one or more of a phospholipid, a detergent or a protein.   
     
     
         27 . (canceled) 
     
     
         28 . The composition of  claim 123 , comprising:
 (a) 15% to 75% by volume olive oil, said oil being saturated with xenon or argon gas;   (b) 25% to 85% by volume aqueous solution;   (c) 10-30 mg/ml phosphocholine;   (d) 10-50 mg/ml BSA; and   (e) 1-5 mg/ml lithocholic acid.   
     
     
         29 - 30 . (canceled) 
     
     
         31 . The composition of  claim 28 , said composition comprised in a gas impermeable container. 
     
     
         32 - 42 . (canceled) 
     
     
         43 . A single serving nutraceutical composition comprising about 25 to 500 ml of a substantially aqueous component and about 0.1 mg to 20 g of dissolved Noble gas, alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin, wherein a portion of the Noble gas in encapsulated to enhance aqueous solubility. 
     
     
         44 - 47 . (canceled) 
     
     
         48 . A method of reducing a marker of inflammation or providing neurological or cardiovascular protection in a subject comprising orally administering an effective amount of a nutraceutical composition of  claim 1 . 
     
     
         49 - 117 . (canceled) 
     
     
         118 . The composition of  claim 1 , wherein the composition comprises a Xenon to water content of at least 2:1 (volume:volume). 
     
     
         119 . The composition of  claim 118 , wherein the composition comprises a Xenon to water content of between 2:1 and 3:1 (volume:volume). 
     
     
         120 . The composition of  claim 1 , wherein the alpha-cyclodextrin comprises modified alpha-cyclodextrin. 
     
     
         121 . The composition of  claim 1 , wherein the beta-cyclodextrin comprises modified beta-cyclodextrin. 
     
     
         122 . The composition of  claim 1 , wherein the gamma-cyclodextrin comprises modified gamma-cyclodextrin. 
     
     
         123 . The composition of  claim 1 , further comprising an edible oil component comprising a dissolved Noble gas.